Boehringer Ingelheim announces commitment to progressing science with the Bouquet Studies
- Details
- Category: Boehringer Ingelheim
Data announced at the American College of Obstetricians and Gynaecologists (ACOG) annual clinical meeting suggest that up to one in ten women are suffering from a condition called hypoactive sexual desire disorder (HSDD) with only a third of these seeking advice or help from their healthcare professional.[1]
Actemra inhibits joint damage and improves physical function of patients with Rheumatoid Arthritis
- Details
- Category: Roche
Roche announced that Actemra (tocilizumab) can significantly inhibit structura[1] damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. Actemra also improved the patients' physical function after one year of therapy, leading to a better quality of life.
International study to evaluate efficacy and safety in treating a leading cause of blindness
- Details
- Category: Bayer
Bayer HealthCare AG and development partner Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD), a leading cause of blindness in adults.
Highlight Potential of Novel Oral Compound for Gaucher Disease
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reported that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compound produced a meaningful impact on key clinical manifestations of Gaucher disease.
Bayer Schering Pharma to market new low-dose oral contraceptive YAZ® in Europe
- Details
- Category: Bayer
Bayer Schering Pharma's new low-dose oral contraceptive YAZ® has been approved in the EU. YAZ® will be the first oral contraceptive on the European market containing the unique progestin drospirenone combined with a low dose of ethinyl estradiol in a new dosing regimen of 24 days of active hormone tablets and four days of placebo.
European Commission grants full approval of HIV protease inhibitor, tipranavir (Aptivus®)
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced that the European Commission has given the full marketing authorisation to its HIV protease inhibitor (PI), Aptivus® (tipranavir). The Commission has fully approved Aptivus ® for the suppression of HIV in highly treatment experienced patients who have developed resistance to other protease inhibitors.
Novo Nordisk researchers nominated for Europe's top innovation prize
- Details
- Category: Novo Nordisk
A team of researchers from Novo Nordisk is nominated for Europe's top innovation prize, Inventor of the Year 2008 Award, that will be presented at a ceremony in Ljubljana, Slovenia, on 6 May by the European Patent Office and the European Commission.
More Pharma News ...
- GlaxoSmithKline commences tender offer to acquire Sirtris Pharmaceuticals
- Abbott, Takeda Conclude TAP Joint Venture
- Esperion Therapeutics Completes $22.75 M Series A Financing
- Lundbeck expands geographical rights for Circadin®
- AstraZeneca Submits sNDA for SYMBICORT® for COPD Treatment
- Novo Nordisk will donate a licence to its small molecule compound library
- Follicular lymphoma: EU approval for Zevalin® as First-Line Consolidation Treatment